According to Tiziana Life Sciences, the FDA has cleared the company’s IND to allow clinical development of intranasal foralumab in Alzheimer’s disease. Earlier this year, Tiziana announced plans to develop foralumab, an intranasal anti-CD3 monoclonal antibody, for the treatment of Alzheimer’s and Type 1 diabetes. The company is also developing intranasal foralumab for the treatment of multiple sclerosis and has announced plans to develop the nasal spray for hemorrhagic stroke and long COVID.
Tiziana acting CEO and Chairman Gabriele Cerrone commented, “The IND clearance is a significant milestone for Tiziana that highlights the strength and the therapeutic potential of foralumab. We are deeply committed to advancing the field of neurodegenerative diseases and bringing much-needed relief to patients suffering from Alzheimer’s with a novel therapeutic approach. We are thrilled to have reached this critical juncture and are eager to move forward with the necessary trials to evaluate the effectiveness of foralumab in Alzheimer’s disease in combination with an FDA approved therapy or as a single agent.”
Read the Tiziana Life Sciences press release.
